摘要Cardiovascular diseases(CVDs)are the leading cause of global mortality,with chronic inflammation playing an important role in their pathogenesis[1].Inflammatory bowel disease(IBD)has been associated with an increased risk of CVDs,including arrhythmias and atherosclerotic disease,potentially mediated by persistent systemic inflammation[2,3].Although observational studies have suggested potential cardiovascular benefits of intestinal anti-inflammatory agents such as 5-aminosalicylates in IBD patients,the conclusive evidence of causal relationships remains lacking[4].To address this gap,we conducted a comprehensive genetic investigation combining two-sample Mendelian randomization(MR),summary data-based Mendelian randomization(SMR),and Bayesian co-localization analyses.Using expression quantitative trait loci(eQTL)data and genome-wide association studies(GWAS)of nine CVD phenotypes,we systematically evaluated the causal effects of intestinal anti-inflammatorv drug targets on car-diovascular outcomes.